An economic evaluation of the current measles vaccination program: A case study in Zhejiang Province, east China

Vaccine. 2019 May 21;37(23):3071-3077. doi: 10.1016/j.vaccine.2019.04.057. Epub 2019 Apr 27.


Objective: To evaluate the economic impact of the current measles vaccination program in Zhejiang Province, east China.

Methods: A decision tree-Markov model with parameters from published literatures, government documents and surveys was developed and used to simulate over 40 years of a birth cohort in Zhejiang Province during the year 2014. The expected cost and effectiveness of the current measles vaccination program was compared against no vaccination. Costs were assessed from the payer's perspective. Benefits were defined as savings on the direct cost of measles treatment, and the effectiveness was measured according to the number of measles cases and deaths averted. The net present value (NPV), benefit-cost ratio (BCR) and incremental cost-effectiveness ratio (ICER) were also calculated. A threshold for cost-effectiveness of less than 3 times the Gross Domestic Product (GDP) per capita was used. One-way sensitivity analysis was performed to assess parameter uncertainties.

Results: The total vaccination cost was estimated to be $2.52 million. The BCR of the current measles program was found to be 6.06 with a NPV of $73.38 million. It was also calculated that a total of 195,165 measles cases and 191 measles-related deaths would be prevented by vaccination. The ICER was approximately $12.91 per case averted and $13,213.43 per death averted, respectively, which was cost-effective. The models were proven to be robust.

Conclusions: The current measles vaccination program appeared to be cost-effective and to offer substantial benefits. The results of this analysis sought to contribute to the justification of future investments to achieve the goal of measles elimination.

Keywords: Economic evaluation; ICER; Measles vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • China
  • Cost-Benefit Analysis*
  • Humans
  • Immunization Programs / economics*
  • Markov Chains
  • Measles / prevention & control*
  • Measles Vaccine / economics*
  • Quality-Adjusted Life Years
  • Vaccination / economics*


  • Measles Vaccine